Klinisch-neuroleptische Untersuchung des N-[(l-Äthyl-pyrrolidin-2-yl)-methyl]-2-methoxy-5-sulfamoyl- Benzamid-Neuroleptikums Sulpirid (Dogmatil®) an akut erkrankten Schizophrenen

Publisher Website
Google Scholar
Abstract
The paper reports on 26 acute, first time or repeatedly diseased schizophrenic patients, who were treated by Sulpiride in a psychiatric ward. The method used was a variant of the single-blind technique of administration and evaluation, the basic conception being that of the ‘neuroleptic threshold’ of Haase. The substance proved to be an intermediary drug between feeble and middle-potent neuroleptics. In doses about 200 mg/ day, it showed a mood-clearing and stimulating effect. The average dosis necessary to reach the neuroleptic threshold was 399 mg Sulpiride, the average time being 6 days. An average dosis of 593.3 mg daily produced in an average time of 11.5 days, dependent from the initial dose, an evident antipsychotic effect. A good indication for Sulpiride therapy seemed to be the inhibited and withdrawn patients, but also the restless, highly productive psychoses, of which 17 from 23 cases showed good results. Extrapyramidal side effects were not important and could easily be kept under control. Only a certain drowsiness after very high doses was registered. The indication of Sulpiride in the ambulatory treatment and in post-psychotic depressions are discussed.

This publication has 0 references indexed in Scilit: